174 related articles for article (PubMed ID: 33459234)
1. SET Protein in Cancer: A Potential Therapeutic Target.
Liang X; Bao X; Chen G
Mini Rev Med Chem; 2021; 21(16):2290-2299. PubMed ID: 33459234
[TBL] [Abstract][Full Text] [Related]
2. Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer.
Hung MH; Chen KF
Expert Opin Ther Targets; 2017 Jul; 21(7):685-694. PubMed ID: 28548025
[TBL] [Abstract][Full Text] [Related]
3. The interaction of SET and protein phosphatase 2A as target for cancer therapy.
Dacol EC; Wang S; Chen Y; Lepique AP
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188578. PubMed ID: 34116173
[TBL] [Abstract][Full Text] [Related]
4. Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy.
Switzer CH; Cheng RY; Vitek TM; Christensen DJ; Wink DA; Vitek MP
Oncogene; 2011 Jun; 30(22):2504-13. PubMed ID: 21297667
[TBL] [Abstract][Full Text] [Related]
5. Targeting Histone Chaperone FACT Complex Overcomes 5-Fluorouracil Resistance in Colon Cancer.
Song H; Zeng J; Roychoudhury S; Biswas P; Mohapatra B; Ray S; Dowlatshahi K; Wang J; Band V; Talmon G; Bhakat KK
Mol Cancer Ther; 2020 Jan; 19(1):258-269. PubMed ID: 31575655
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis.
Saddoughi SA; Gencer S; Peterson YK; Ward KE; Mukhopadhyay A; Oaks J; Bielawski J; Szulc ZM; Thomas RJ; Selvam SP; Senkal CE; Garrett-Mayer E; De Palma RM; Fedarovich D; Liu A; Habib AA; Stahelin RV; Perrotti D; Ogretmen B
EMBO Mol Med; 2013 Jan; 5(1):105-21. PubMed ID: 23180565
[TBL] [Abstract][Full Text] [Related]
7. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment.
Mukhopadhyay A; Tabanor K; Chaguturu R; Aldrich JV
Cancer Biol Ther; 2013 Oct; 14(10):962-72. PubMed ID: 24025258
[TBL] [Abstract][Full Text] [Related]
8. HSF1-mediated regulation of tumor cell apoptosis: a novel target for cancer therapeutics.
Kumar S; Tomar MS; Acharya A
Future Oncol; 2013 Oct; 9(10):1573-86. PubMed ID: 24106905
[TBL] [Abstract][Full Text] [Related]
9. Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.
Farrell AS; Allen-Petersen B; Daniel CJ; Wang X; Wang Z; Rodriguez S; Impey S; Oddo J; Vitek MP; Lopez C; Christensen DJ; Sheppard B; Sears RC
Mol Cancer Res; 2014 Jun; 12(6):924-39. PubMed ID: 24667985
[TBL] [Abstract][Full Text] [Related]
10. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.
Jafari A; Rezaei-Tavirani M; Farhadihosseinabadi B; Taranejoo S; Zali H
Cancer Invest; 2020 May; 38(5):310-328. PubMed ID: 32274949
[TBL] [Abstract][Full Text] [Related]
11. The Role of CtBP1 in Oncogenic Processes and Its Potential as a Therapeutic Target.
Blevins MA; Huang M; Zhao R
Mol Cancer Ther; 2017 Jun; 16(6):981-990. PubMed ID: 28576945
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia.
Agarwal A; MacKenzie RJ; Pippa R; Eide CA; Oddo J; Tyner JW; Sears R; Vitek MP; Odero MD; Christensen DJ; Druker BJ
Clin Cancer Res; 2014 Apr; 20(8):2092-103. PubMed ID: 24436473
[TBL] [Abstract][Full Text] [Related]
13. Targeting p73--a potential approach in cancer treatment.
Slade N; Horvat A
Curr Pharm Des; 2011; 17(6):591-602. PubMed ID: 21391909
[TBL] [Abstract][Full Text] [Related]
14. Distribution of SET/I2PP2A protein in gastrointestinal tissues.
Umata K; Sakai Y; Ikeda S; Tsuji S; Kawasaki H; Ohama T; Sato K
PLoS One; 2019; 14(9):e0222845. PubMed ID: 31557212
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic effects of SET/I2PP2A inhibitors on canine melanoma.
Enjoji S; Yabe R; Fujiwara N; Tsuji S; Vitek MP; Mizuno T; Nakagawa T; Usui T; Ohama T; Sato K
J Vet Med Sci; 2015 Nov; 77(11):1451-6. PubMed ID: 26062569
[TBL] [Abstract][Full Text] [Related]
16. Higher content of microcystin-leucine-arginine promotes the survival of intrahepatic cholangiocarcinoma cells via regulating SET resulting in the poorer prognosis of patients.
Gu S; He W; Yan M; He J; Zhou Q; Yan X; Fu X; Chen J; Han X; Qiu Y
Cell Prolif; 2021 Feb; 54(2):e12961. PubMed ID: 33241617
[TBL] [Abstract][Full Text] [Related]
17. 14-3-3ΞΆ as a prognostic marker and therapeutic target for cancer.
Neal CL; Yu D
Expert Opin Ther Targets; 2010 Dec; 14(12):1343-54. PubMed ID: 21058923
[TBL] [Abstract][Full Text] [Related]
18. Novel oncoprotein EPS8: a new target for anticancer therapy.
Li YH; Xue TY; He YZ; Du JW
Future Oncol; 2013 Oct; 9(10):1587-94. PubMed ID: 24106906
[TBL] [Abstract][Full Text] [Related]
19. New Cytotoxic Natural Products from the Red Sea Sponge
Abdelhameed RFA; Habib ES; Eltahawy NA; Hassanean HA; Ibrahim AK; Mohammed AF; Fayez S; Hayallah AM; Yamada K; Behery FA; Al-Sanea MM; Alzarea SI; Bringmann G; Ahmed SA; Abdelmohsen UR
Mar Drugs; 2020 May; 18(5):. PubMed ID: 32375235
[TBL] [Abstract][Full Text] [Related]
20. Non-homologous DNA end joining in anticancer therapy.
Pastwa E; Malinowski M
Curr Cancer Drug Targets; 2007 May; 7(3):243-50. PubMed ID: 17504121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
